Glenmark Pharma Q2 Results: Net profit plunges 56% to Rs 264 crore, revenue down at Rs 4,247 cr
Economic Times
Glenmark Pharmaceuticals experienced a 56.78 percent drop in consolidated
profit after tax during the September quarter. Total revenue from operations
decreased to Rs 4,247.32 crore compared to the previous year. The company's
total expenses also decreased during the same period, indicating some
operational efficiency. A subsidiary of Glenmark Pharma entered into a
settlement for USD 15 million with Humana Inc.